Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2455-2458

  Folsom, Aaron R ^a   Peacock, James M ^a   Boerwinkle, Eric ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CANCER INCIDENCE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEGRO; NEOPLASM; PRIORITY JOURNAL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 SERINE PROTEASE GENE; PROSPECTIVE STUDY; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; UNITED STATES;

EID: 38849084481     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0502     Document Type: Article

References (17)

1. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-60.
2. Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 1992;2:253-61.
3. Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, Tyroler HA. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991;51:3198-203.
4. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
5. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
6. Friis S, Olsen JH. Statin use and cancer risk: an epidemiologic review. Cancer Invest 2006;24:413-24.
7. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33.
8. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
9. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42.
11. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
12. ARIC Investigators. ARIC Study Web site [accessed 2007 June 1]. Available from: http://www.cscc.unc.edu/aric/.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
15. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982;36:936-42.
16. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28-36.
17. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-102.